POSTERIOR REVERSIBLE LEUKOENCEPHALOPATHY SYNDROME DEVELOPING SECONDARY TO SUNITINIB THERAPY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA

Basit Öğe Kaydı
dc.authoridElkıran, Emin Tamer/0000-0001-6681-7249
dc.authoridharputluoglu, hakan/0000-0001-8537-5941;
dc.authorwosidElkıran, Emin Tamer/ABI-8192-2020
dc.authorwosidharputluoglu, hakan/ABI-6451-2020
dc.authorwosidtemelli, Oztun/ABE-6986-2020
dc.contributor.authorKaplan, Nihal Bozdag
dc.contributor.authorHarputluoglu, Hakan
dc.contributor.authorDikilitas, Mustafa
dc.contributor.authorElkiran, Emin Tamer
dc.contributor.authorTemelli, Oztun
dc.date.accessioned2024-08-04T20:44:26Z
dc.date.available2024-08-04T20:44:26Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPosterior reversible encephalopathy syndrome (PRES) is characterized by vasogenic edema occurring generally in parietal and occipital areas of the brain as a result of different etiologic causes and it is diagnosed by means of clinical and radiologic assessment. Sunitinib is an orally administered tyrosine kinase inhibitor used in the treatment of renal cell carcinoma with its antiangiogenic and antitumor effects. Fatigue, nausea-vomiting, diarrhea, hypertension, cardiotoxicity, hypothyroidism, neutropenia, and skin toxicity are among common side effects associated with sunitinib therapy. The current report presents a female patient with metastatic papillary renal cell cancer who developed posterior reversible encephalopathy syndrome as determined by means of clinical and radiologic assessment at 8 months of sunitinib therapy and who completely recovered with antihypertensive, antiepileptic, and antiedema therapy.en_US
dc.identifier.doi10.19193/0393-6384_2018_1_6
dc.identifier.endpage42en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85045702796en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage39en_US
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2018_1_6
dc.identifier.urihttps://hdl.handle.net/11616/98246
dc.identifier.volume34en_US
dc.identifier.wosWOS:000424878600006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPosterior reversible encephalopathy syndromeen_US
dc.subjectsunitiniben_US
dc.subjectearly diagnosisen_US
dc.titlePOSTERIOR REVERSIBLE LEUKOENCEPHALOPATHY SYNDROME DEVELOPING SECONDARY TO SUNITINIB THERAPY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMAen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu